Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2000

View Archived Issues

Aurora acquires Quorum Sciences

Antex licenses lantibiotics with promise for antibiotic-resistant bacteria

Complete analysis of data from Neotrofin phase II trial

Vertex expands product pipeline

Posaconazole active against histoplasmosis in immunocompromised animals

Cryptococcus neoformans potently inhibited by ravuconazole in recent in vitro study

ABT-773 effective against disseminated MAC infection in vivo

Pharmacokinetics, disposition and metabolism of new hepatic antiinflammatory TA-510

Chemotherapeutic potential of competitive glyoxalase I inhibitor evaluated in tumor-bearing mice

E-6060, a potential new therapy for antibody-dependent autoimmune diseases

Vivus begins patient enrollment for female sexual dysfunction trial

Antisoma licenses thioplatin from German cancer center

Immunotherapy with beta-alethine useful in minimal residual disease

Safe new agents from Ajinomoto with potential in irritable bowel syndrome

Substituted aza-oxindoles which inhibit protein tyrosine or serine/threonine kinases

Patient enrollment begins in phase I trial of Cotara for colorectal cancer

Novo Nordisk's new potassium channel openers specifically claimed for diabetes

Inflammatory cytokine-reducing compounds designed at Celgene

Novel GH secretagogues claimed by BMS

Boehringer Ingelheim presents new series of inhibitors of signal transduction

Subtype-selective estrogen receptor modulators described by Signal, AxyS

BioChem Pharma to acquire CliniChem

Zevalin effective and safe in refractory, heavily pretreated NHL patients

License to new drug delivery technology obtained by Kos

Melacine as adjuvant therapy in melanoma: phase III data reported at SBT meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...